Filer Snapshot

GENMAB A/S

CIK 0001434265. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

5

Latest filing

17 Feb 2026

Industry

Pharmaceutical Preparations

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13D/G stake for MRUS. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13D/G history Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

MRUS

30 Dec 2025 · 0% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC filing 20-F

20-F filed on 17 Feb 2026 for CIK 0001434265.

View source filing
Listed symbols
GMAB on Nasdaq, GNMSF on OTC
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Largest active 13D stakes

Active large-stake positions disclosed in parsed Schedule 13D filings.

MRUS
How to read these SEC ownership signals
  • Read each filing family separately: 13F portfolios, 13D/G large stakes, and Forms 3/4/5 owner positions answer different SEC disclosure questions.
  • Open the linked research path when you need the filing, CIK, issuer, or CUSIP trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 2 identity fields
SEC industry group
Pharmaceutical Preparations (Office of Life Sciences)
Business address
Toldbodgade 33, 1253 Copenhagen K, Denmark, 00000

Filer intelligence

What SEC filings say about GENMAB A/S

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

Quick read

  • 1 recent 13D/G stake row found; top row is MRUS at 0% ownership.
  • Forms 3/4/5 show insider context for MRUS worth $0.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

Open
13D/G stakes 1 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 1 rows

Officer, director, and 10% owner holdings or transactions.

Open

13D/G large-stake context

MRUS

30 Dec 2025 · Common Shares, Euro 0.09 nominal value per share

0%
Issuer page 13D/G history

Forms 3/4/5 insider context

MRUS

26 Dec 2025 · 10% owner

$0
Issuer page Owner page

Latest update

What changed recently for GENMAB A/S

New fact period available

Latest financial period: Q4 2025. Open the source-backed page to inspect the fresh filing or facts context.

Update date

17 Feb 2026

Page type

Company facts

Latest period

Q4 2025

SEC-backed company facts were refreshed from filings filed on 17 Feb 2026.

Open company facts Browse recent public updates

Benchmark Context

Benchmark context for this company

GENMAB A/S has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest financial period: Q4 2025. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 17 Feb 2026.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0001434265 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
5
First seen
12 Feb 2025
Latest filing
17 Feb 2026
Entity
Company

Observed form types

20-F SCHEDULE 13D SCHEDULE 13D/A SCHEDULE 13G

CIK-linked evidence first

GENMAB A/S SEC filings GENMAB A/S 13D/G history GENMAB A/S owner filings GENMAB A/S company facts GMAB holder history Open SEC filing index

Industry context: Pharmaceutical Preparations.

Latest Filings

Showing the latest 5 of 5 SEC filings for GENMAB A/S.

20-F

20-F filing

Filing date
17 Feb 2026
Reporting date
31 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
30 Dec 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D

SCHEDULE 13D filing

Filing date
19 Dec 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G

SCHEDULE 13G filing

Filing date
14 Nov 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
20-F

20-F filing

Filing date
12 Feb 2025
Reporting date
31 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .